# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-23-001933
**Filing Date:** 2023-1
**Character Count:** 17140
**Document Hash:** d6f9ba02d6e2d6930bfc602464d51d58
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001933.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0001213900-23-001933

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230110

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 23520519

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 310, 815 W. HASTINGS STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1B4
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** SUITE 310, 815 W. HASTINGS STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1B4

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): January 10, 2023**

**INMED PHARMACEUTICALS INC.**

**(Exact Name of Company as Specified in Charter)** 

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39685** | **98-1428279** |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **InMed Pharmaceuticals Inc.**<br> **Suite 310 - 815 W. Hastings Street,**<br> **Vancouver** **, B.C.**<br> **Canada** | **V6C 1B4** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Company's telephone number, including area code: (604) 669-7207**

**Not applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Shares, no par value** | **INM** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On January 10, 2023, the Company outlined key accomplishments from 2022 and provides business update and catalysts for 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [News release, dated January 10, 2023](ea171496ex99-1_inmedpharma.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | INMED PHARMACEUTICALS INC. | INMED PHARMACEUTICALS INC. |
| Date: January 10, 2023 | By: | /s/ Eric A Adams |
|  |  | Eric A Adam <br> President & CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](ex99-1_001.jpg) | <br> **NASDAQ: INM**<br>Suite 310-815 W. Hastings St.<br> Vancouver, BC, Canada V6C 1B4<br> Tel: +1.604.669.7207<br> Email: info@inmedpharma.com<br> www.inmedpharma.com |

---

**InMed Provides Business Update and Milestones for 2023**

● **Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023** 

● **Progress preclinical research in glaucoma in preparation for human trials** 

● **Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's** 

Vancouver, BC – January 10, 2023 – InMed Pharmaceuticals Inc. ("**InMed**" or the "**Company**") (**Nasdaq: INM**), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlines key accomplishments from 2022 and provides business update and catalysts for 2023.

"Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how. Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters," commented Eric A. Adams, InMed President and CEO.

**<u>Key accomplishments in 2022:</u>**

**INM-755 in Epidermolysis Bullosa**

● Activated 11 clinical trial sites in seven countries for the Phase 2 study

● Expanded from adult subjects to include adolescents following independent review of early safety data

● Progressed clinical trial with enrollment and treatment of 15 patients, with the 16<sup>th</sup> patient enrolled for treatment in early January 2023

**INM-088 in Glaucoma**

● Completed a pre-Investigational New Drug ("pIND") application meeting with the FDA and gained alignment on the proposed design of the Phase 1-2 clinical trial program

● Advanced preclinical toxicology in preparation for clinical trial

**INM-900 Series in Neurodegenerative diseases**

● Launched and advanced neurodegenerative disease program following promising research showing how specific cannabinoid analogs may inhibit or slow disease progression

● Filed international patent application using rare cannabinoids and analogs for the potential treatment of neurodegenerative diseases

● Grant received by research partner from NSERC to support preclinical research

**Cannabinoid Analogs**

● Published North American patent for several cannabinoid analogs with broad claims of molecular structure, uses and methods of manufacturing

● Initiated research collaboration with leading expert to screen cannabinoid analogs for pharmacological properties and potential therapeutic applications

● Advanced two analogs for further lead identification in neurogenerative disease

**Commercial**

● Launched B2B sales of premium rare cannabinoids CBT, CBDV and THCV in addition to existing CBC sales in the health and wellness sector via our subsidiary, BayMedica

**Publications**

● Published peer-reviewed study highlighting potential role of THCV, CBC and other rare cannabinoids on various skin conditions

● Published peer-reviewed article on the use of CBN as a potential treatment for glaucoma

**Corporate**

● Raised in excess of $16M through several financings to fund advancement of pharmaceutical programs and corporate activities through the end of calendar year 2023.

**<u>Business update and upcoming milestones:</u>**

**INM-755 – Phase 2 clinical trial in the treatment of Epidermolysis Bullosa**

To date, the Phase 2 clinical trial has enrolled 16 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023. The clinical trial is evaluating the safety of INM-755 cannabinol cream and its preliminary efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa. As the trial is double blinded, InMed will remain blinded to INM-755 treatment outcomes until the last patient has completed treatment and the database is locked and analyzed.

**INM-088 – Advancing towards human trials**

The Company continues to conduct the required preclinical work, including toxicology studies, and has planned several GLP studies in 2023 in advance of human clinical trials. Outcomes from our pre-IND meeting with the FDA in 2022 provided important feedback on our proposed preclinical studies and for the design of human clinical trials. Advancing to human trials in a disease indication with a very large patient population like glaucoma will be a significant development for the Company. We are on track to begin this clinical trial in 2024.

**INM-900 – Developing a new approach in neurodegenerative disease**

Cannabinoids are known to be highly lipophilic and can cross the blood brain barrier, making the non-psychedelic cannabinoids attractive pharmaceutical agents for targeting neurological disorders. Our pipeline was expanded this year with the addition of our neurodegenerative disease program. With recent promising preclinical data, InMed plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. Our research demonstrated the neuroprotective effects of specific cannabinoid analogs and their potential to improve neuronal function. Two cannabinoid analogs are being assessed in *in vivo* models of neurodegenerative disease. Our approach may target multiple novel disease pathways versus the majority of drugs currently in clinical development for these diseases.

**Novel cannabinoid analogs – protecting the R&D investment**

InMed continues to develop a valuable library of novel, proprietary cannabinoid analogs. These analogs are being selectively screened and developed for targeting specific disease outcomes, safety profiles, and/or pharmacological properties such as improved delivery. In addition, these novel cannabinoid analogs are patentable, increasing their commercial attractiveness for internal development or as licensing candidates to other drug development companies.

**BayMedica commercial business**

Our efforts in the first half of 2022 were primarily focused on advancing the commercial side of the business following the acquisition of BayMedica in late 2021. Although BayMedica continues to be a reliable source of rare cannabinoids, demand has not accelerated as quickly as anticipated for a variety of reasons. As we enter 2023, we will continue to evaluate strategic options and long-term supply agreements for this business segment. In 2022, BayMedica supplied highly pure rare cannabinoids for use in Radicle Science, Inc.'s Radicle Energy rare cannabinoid study to assess the effects of delta-9 THCV on energy, focus/attention, appetite and weight/body mass index (BMI). The study is part of Radicle Science's large-scale evaluations of several rare cannabinoids, involving up to 10,000 participants in total. The consumer-driven trial is complete and results are expected in the first half of 2023, providing much needed supportive data to demonstrate the effects of delta-9 THCV.

**Business development**

The Company continues to evaluate and pursue business development opportunities which align strategically with the Company's current direction and pharmaceutical programs.

In light of current capital market challenges, the Company's main priority is to continue to adequately resource the Company's activities while maintaining a healthy balance sheet. With the completion of recent financings and depending on how we prioritize investment into our various development activities, InMed has a projected cash runway into early 2024, allowing the Company to hit certain material milestones over the coming year which we believe will increase shareholder value.

Management looks forward to updating shareholders over the coming months.

**About InMed:**

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.

**Investor Contact:**

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com

**Cautionary Note Regarding Forward-Looking Information:** 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: having a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know; being very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters; research showing how specific cannabinoid analogs may inhibit or slow disease progression; additional prospective patients have been identified for screening at the clinical sites; extending the enrollment period to the end of March 2023; advancing preclinical toxicology and having several GLP studies planned for 2023 in advance of human clinical trials; being on track to begin this clinical trial in 2024; plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease; analogs being selectively screened and developed for targeting specific disease outcomes, safety profiles, and/or pharmacological properties such as improved delivery; developing a valuable library of novel, proprietary cannabinoid analogs; commercial attractiveness of analogs for internal development or as licensing candidates; evaluating strategic options and long-term supply agreements for the BayMedica commercial segment; Radicle Science results expected in the first half of 2023; evaluating and pursuing business development opportunities which align strategically with the Company's current direction and pharmaceutical programs; having projected cash runway into early 2024, depending on how we prioritize our investment into various development activities; belief that hitting certain material milestones will increase shareholder value; all plans for our preclinical and clinical programs; being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.